



**HAL**  
open science

## **Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies**

Sayda Dhaouadi, Rahma Ben Abderrazek, Thomas Loustau, Cherine Abou-Faycal, Ayoub Ksouri, William Erne, Devadarssen Murdamoothoo, Matthias Morgelin, Andreas Kungl, Alain Jung, et al.

### ► **To cite this version:**

Sayda Dhaouadi, Rahma Ben Abderrazek, Thomas Loustau, Cherine Abou-Faycal, Ayoub Ksouri, et al.. Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies. *Frontiers in Immunology*, 2021, 12, <10.3389/fimmu.2021.635166>. <hal-04689716>

**HAL Id: hal-04689716**

**<https://hal.science/hal-04689716v1>**

Submitted on 5 Sep 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization



# Novel Human Tenascin-C Function-Blocking Camel Single Domain Nanobodies

## OPEN ACCESS

### Edited by:

Manuela Mengozzi,  
Brighton and Sussex Medical School,  
United Kingdom

### Reviewed by:

Bhalchandra Mirlekar,  
University of North Carolina at Chapel  
Hill, United States  
Antonio Maurizi,  
University of L'Aquila, Italy

### \*Correspondence:

Balkiss Bouhaouala-Zahar  
balkiss.bouhaouala@fmt.utm.tn;  
balkiss.bouhaouala@pasteur.utm.tn

†These authors have contributed  
equally to this work

‡Deceased

### Specialty section:

This article was submitted to  
Inflammation,  
a section of the journal  
Frontiers in Immunology

**Received:** 29 November 2020

**Accepted:** 19 February 2021

**Published:** 15 March 2021

### Citation:

Dhaouadi S, Ben Abderrazek R,  
Loustau T, Abou-Faycal C, Ksouri A,  
Erne W, Murdamoothoo D,  
Mörgelin M, Kungl A, Jung A,  
Ledrappier S, Benlasfar Z, Bichet S,  
Chiquet-Ehrismann R, Hendaoui I,  
Orend G and Bouhaouala-Zahar B  
(2021) Novel Human Tenascin-C  
Function-Blocking Camel Single  
Domain Nanobodies.  
*Front. Immunol.* 12:635166.  
doi: 10.3389/fimmu.2021.635166

Sayda Dhaouadi<sup>1</sup>, Rahma Ben Abderrazek<sup>1</sup>, Thomas Loustau<sup>2†</sup>, Chérine Abou-Faycal<sup>2†</sup>, Ayoub Ksouri<sup>1†</sup>, William Erne<sup>2†</sup>, Devadarssen Murdamoothoo<sup>2</sup>, Matthias Mörgelin<sup>3</sup>, Andreas Kungl<sup>4,5</sup>, Alain Jung<sup>6</sup>, Sonia Ledrappier<sup>6</sup>, Zakaria Benlasfar<sup>1</sup>, Sandrine Bichet<sup>7</sup>, Ruth Chiquet-Ehrismann<sup>7‡</sup>, Ismaïl Hendaoui<sup>7</sup>, Gertraud Orend<sup>2</sup> and Balkiss Bouhaouala-Zahar<sup>1,8\*</sup>

<sup>1</sup> Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Université Tunis El Manar, Tunis, Tunisia,

<sup>2</sup> Université Strasbourg, INSERM U1109 – The Tumor Microenvironment group, Hôpital Civil, Institut d'Hématologie et d'Immunologie, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France, <sup>3</sup> Colzyx AB, Lund, Sweden, <sup>4</sup> Institute of Pharmaceutical Sciences, Karl Franzens University Graz, Graz, Austria, <sup>5</sup> Antagonis Biotherapeutics GmbH, Graz, Austria, <sup>6</sup> Tumor Bank Centre Paul Strauss, Strasbourg, France, <sup>7</sup> Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland, <sup>8</sup> Faculté de Médecine de Tunis, Université Tunis el Manar, Tunis, Tunisia

The extracellular matrix (ECM) molecule Tenascin-C (TNC) is well-known to promote tumor progression by multiple mechanisms. However, reliable TNC detection in tissues of tumor banks remains limited. Therefore, we generated dromedary single-domain nanobodies Nb3 and Nb4 highly specific for human TNC (hTNC) and characterized the interaction with TNC by several approaches including ELISA, western blot, isothermal fluorescence titration and negative electron microscopic imaging. Our results revealed binding of both nanobodies to distinct sequences within fibronectin type III repeats of hTNC. By immunofluorescence and immunohistochemical imaging we observed that both nanobodies detected TNC expression in PFA and paraffin embedded human tissue from ulcerative colitis, solid tumors and liver metastasis. As TNC impairs cell adhesion to fibronectin we determined whether the nanobodies abolished this TNC function. Indeed, Nb3 and Nb4 restored adhesion of tumor and mesangial cells on a fibronectin/TNC substratum. We recently showed that TNC orchestrates the immune-suppressive tumor microenvironment involving chemorepulsion, causing tethering of CD11c+ myeloid/dendritic cells in the stroma. Here, we document that immobilization of DC2.4 dendritic cells by a CCL21 adsorbed TNC substratum was blocked by both nanobodies. Altogether, our novel TNC specific nanobodies could offer valuable tools for detection of TNC in the clinical practice and may be useful to inhibit the immune-suppressive and other functions of TNC in cancer and other diseases.

**Keywords:** nanobody, extracellular matrix, tenascin-c, tumor biomarker, interaction modeling, diagnostic tool, therapeutic tool, fibronectin type III repeat

## INTRODUCTION

Tenascin-C (TNC), discovered over three decades ago, is one of the ECM molecules that is highly expressed in tumors such as breast, colorectal and gastric cancers (1–4). High TNC expression levels correlate with shortened lung metastasis-free survival in breast cancer and overall survival in glioma patients (5, 6). TNC is a large modular hexameric glycoprotein (7). Each TNC subunit displays a central oligomerization domain, followed by 14.5 epidermal growth factor (EGF)-like repeats (three disulfide bridges per EGF-repeat), 17 fibronectin type 3 (FNIII) repeats (eight constant and nine additional repeats domains that are subject to alternative splicing) and a globular fibrinogen domain (7). At physiological level, TNC is transiently expressed during organogenesis (8) and its expression is largely restricted to a few sites in the adult organism such as in some stem cell niches, tendons, and reticular fibers of lymphoid organs (9). Interestingly, high TNC levels are also found in milk of breast feeding HIV+ mothers (10). At pathological level, TNC was shown to act at multiple levels to promote tumor progression into cancer by enhancing survival, proliferation and invasion of tumor cells, driving the formation of new but poorly functional blood vessels and to corrupt anti-tumor immunity, altogether enhancing metastasis. In addition to tumors, TNC is also highly up-regulated in wound healing, fibrosis and chronic inflammation (11, 12). Recently, high TNC levels were also associated with more severe COVID19 symptoms (13). Using stochastic tumorigenesis models with engineered high and low levels of TNC it was formally proven that TNC indeed is a promoter of tumor progression (14). TNC is inducing and activating a wide range of cellular signaling pathways such as Wnt, Notch, JNK and TGF $\beta$  (14–17). TNC also acts on stromal and immune cells thereby promoting tumor angiogenesis and immune escape (18–22). The distinct spatio-temporal expression pattern of TNC is highly regulated (23). *In vitro* studies demonstrated that various stimuli such as EGF, TGF $\beta$ , b-FGF, and TNF- $\alpha$ , can induce expression of TNC in breast cancer stroma (5, 24). In cancerous breast tissues, EGF induced TNC via its receptor EGFR which activated oncogenic Ras signaling. Mammary tumor cells also produced transforming growth factor  $\beta$ 1 (TGF $\beta$ 1), which induced TNC expression in the surrounding stroma (25, 26). Due to defective autophagy TNC seems to be highly abundant in triple negative breast cancer (27). An overview of factors regulating TNC expression is presented in Giblin et al. (23).

Given its high expression in cancer tissues as well as its inflammation promoting actions, several efforts have been launched to specifically detect TNC *in situ* as well as to inhibit its main pathological effects. These approaches included down regulation of TNC expression with siRNA or aptamers (28–32) and the use of TNC-specific antibodies for the delivery of drugs or radiotherapy (33–35). Moreover, numerous monoclonal antibodies recognizing TNC have been developed. However, all generated tools have their intrinsic limitations and caveats. In particular, antibodies may not reach the target tissue or can raise an immune response and formalin fixation, usually used in routine pathology service, can impair epitope recognition

(36, 37). Thus, better molecular tools are needed for specific and sensitive recognition and potential targeting of TNC. To overcome these limitations, recombinant nanobodies (Nbs) with their remarkable characteristics (i.e., high stability, solubility and specificity and low immunogenicity) may provide a solution (38–43).

Here, we have generated two “best in class” nanobodies (Nb3 and Nb4) that recognize specifically TNC with high affinity by ELISA and staining of formalin fixed and fresh frozen tissues, emphasizing novel opportunities for early diagnosis and potential monitoring of cancer progression. Therefore, these nanobodies may be useful for applications in routine cancer diagnosis and for future *in vivo* targeting of TNC in cancer. On the other hand, as TNC impairs cell adhesion on a fibronectin substratum, we determined whether the nanobodies abolished this function of TNC. Indeed Nb3 and Nb4 restored adhesion of human osteosarcoma and mesangial cells on the fibronectin/TNC substratum. Interestingly, we observed that immobilization of DC2.4 dendritic cells on a TNC substratum in context of CCL21 (22) was blocked by Nb3 and Nb4. Finally, by modeling the Nb/TNC interaction we determined the putative amino acid residues involved in complex formation. Altogether, we demonstrated that our two novel TNC-specific nanobodies display valuable characteristics for detection of TNC *in situ*, and revealed their potential as therapeutic tools for inhibition of immune-suppressive and other functions of TNC.

## MATERIALS AND METHODS

### Purification of Recombinantly Expressed hTNC

HEK 293/hTNC cells, previously stably transfected with the human TNC coding sequence (hTNC) were used to produce hTNC as previously described (44, 45). Briefly, cells were cultured in Dulbecco’s Minimal Essential Medium (DMEM, catalog number 11995040 Gibco Life Technologies, Inc., Paisley, Scotland) supplemented with 10 % (v/v) fetal calf serum (FCS, catalog number 2-01F90-I BioConcept, Allschwil, Switzerland), 10.25  $\mu$ g/mL G418 and 1.5  $\mu$ g/mL puromycin under a 5% CO<sub>2</sub> atmosphere at 37°C. The recombinant hTNC was purified from the conditioned medium lacking FCS as previously described (44). Briefly, fibronectin was removed from the conditioned medium by gelatin-agarose affinity chromatography (46, 47), and the flow through was purified by a nickel affinity chromatography column (48). The purity of the protein was checked by Coomassie Blue stained 7% SDS-PAGE and by western-blot, under reducing and non-reducing conditions. The concentration of hTNC was determined by Bradford assay (catalog number 500-0006 Bio-Rad Laboratories, Hercules, CA, USA).

### *E. coli* Strains and Vector

The phage display vector pMECS of 4,510 bp was utilized to construct the VHH library, hosted in *E. coli* strain TG1 (generously provided by Prof. Serge Muyldermans, VUB Brussel, Belgium). This phagemid vector contains a sequence encoding a PelB leader signal to secrete the cloned VHH-encoded Nb in

the periplasm with two C-terminal Hemagglutinin (HA) and 6X Histidine (6X His) tags for VHH-detection, when hosted in *E. coli* strain WK6 (49).

## Generation of the Phage-Display VHH-Library

The anti-hTNC nanobody phage-display VHH-library was constructed as previously described with slight modifications (39, 49, 50). Briefly, 3 days after the last boost of antigen injection, 150 mL of anti-coagulated blood sample was collected from the jugular vein of the immunized dromedary as recently detailed (51). Peripheral blood mononuclear cells (PBMCs) were extracted by density gradient centrifugation using Lymphoprep (catalog number 17-829 LONZA, Basel, Switzerland). Subsequently, total RNA was extracted and purified. An amount of 40 µg of total RNA was reverse transcribed into cDNA with oligo-dT primer and the SuperScript II First-Strand Synthesis System for RT-PCR (catalog number 18064-014 Invitrogen, Carlsbad, CA, USA). Thereafter, cDNA fragments were used as template to amplify heavy-chain IgG encoding variable domains using specific primers [CALL001 (5'-GTCCTGGCTGCTCTTCTACAAGG-3') and CALL002 (5'-GGTACGTGCTGTTGAACTGTTCC-3')]. The 700 bp PCR fragment (VHH-CH2 without CH1 exon, corresponding to heavy-chain antibodies) was purified from a 1% agarose gel using the Qiaquick gel extraction kit (catalog number 28704 Qiagen, Hilden, Germany). Subsequently, these sequences were used as template in a nested PCR to amplify VHH-only variable domains with nested-PCR primers [SM017 (5'-CCAGCCGGCC ATGGCTGCATGGTGCAGCTGGTGGAGTCTGG-3') and PMCF (5'-CTAGTGC GGCCGCTGAGGAGACGGTGACCTG GGT-3')], annealing at the Framework 1 and Framework 4 regions, including NcoI and NotI restriction sites, respectively (catalog numbers R0193T and R3189M New England Biolabs, UK, respectively). The PCR product was ligated into the pMECS phagemid vector (T4 DNA Ligase, catalog number 15224-041 Invitrogen, Carlsbad, CA, USA) using a molar ratio 1:3 in favor of the inserts. Freshly prepared electro-competent *E. coli* TG1 cells were transformed by the ligated product and plated overnight (O/N) on selective Luria-Bertani Miller (LB) media supplemented with (100 µg/mL) ampicillin (catalog number 271896 Sigma Aldrich, MO, USA) and glucose 2% (catalog number G8270 Sigma Aldrich, MO, USA). Colonies were recovered from the overnight-incubated plates at 37°C. Library size was estimated by serial dilutions.

## Selection of Anti-hTNC Nanobodies (Nbs)

A representative repertoire of the VHH library was displayed on phage particles using M13KO7 helper phage infection (catalog number 170-3578 New England, BioLabs, UK). Three consecutive rounds of immuno-affinity selection were carried out on 96-well microtiter plates (catalog number M5785-1CS Sigma Aldrich, MO, USA) pre-coated with hTNC (1 µg/panning, O/N at 4°C). After each round of biopanning, bound phage particles were eluted (100 mM triethylamine, pH 10.0, catalog number T0886 Sigma Aldrich, MO, USA) and immediately neutralized with 1 M Tris-HCl, pH 7.4 (catalog number CE234

GeneON, Germany) and used to infect exponentially growing TG1 *E. coli*. Following the third round of biopanning, individual colonies were randomly picked. VHH expression was induced with 1 mM isopropyl-D-thiogalactopyranoside (IPTG, catalog number 2900245 5PRIME, Germany) in the periplasmic bacterial compartment. Solid phase ELISA of each periplasmic extract was carried out on hTNC (1 µg/mL), using a mouse anti-HA antibody (catalog number H9658 Sigma Aldrich, MO, USA) and goat anti-mouse IgG-peroxidase antibody (catalog number A9044 Sigma Aldrich, MO, USA).

## VHH Sequence Analysis

The VHH sequences of clones that scored positive in periplasmic extract-ELISA were determined using the Genomic platform of Institut Pasteur de Tunis facilities (ABI Prism 3100 genetic analyzer; Applied Biosystems, Foster City, CA, USA). The VHH nucleotide sequences were obtained using the ABI PRISM™ BigDye Terminator v3.1 Cycle Sequencing Reaction Kit (catalog number 4337454 Applied Biosystems, USA).

## Production, Purification, and Characterization of hTNC-Specific Nbs

Recombinant vectors of selected positive clones with highest binding capacity to hTNC were used to transform WK6 electrocompetent cells. Nb production was performed in shake flasks by growing each recombinant bacteria in Terrific Broth medium (TB, catalog number 743-29175 BD Biosciences, FL, USA) supplemented with ampicillin (100 µg/mL) and 0.1% glucose. The Nb periplasmic expression was subsequently induced with 1 mM IPTG, O/N at 28°C. The periplasmic extract obtained by osmotic shock was loaded on a His-Select column (NiNTA, catalog number 1018544 Qiagen, Hilden, Germany). The His-tagged hTNC-specific Nbs were eluted with 500 mM imidazole (catalog number I-0125 Sigma Aldrich, MO, USA) and an amount of 5 µg was checked on a 15% SDS gel upon-PAGE (Bio Rad), following dialysis towards PBS with a 12 kDa cut-off membrane (catalog number D9527-100FT Sigma Aldrich, MO, USA). The final yield was determined using Bradford assay (catalog number 500-0006 Bio-Rad Laboratories, Hercules, CA, USA) and the molar concentration was estimated using the theoretical extinction coefficient of the VHH sequence. The specificity of the purified anti-hTNC nanobodies was assessed by ELISA. Briefly, 0.5 µg/mL of hTNC was coated onto microtiter plates O/N at 4°C and unspecific sites were blocked with 1% (w/v) gelatin (catalog number 48723 Fluka Analytical, USA) supplemented with PBS/0.05% Tween-20 at 37°C for 2 h. Affinity-purified Nb was added (5 µg/mL, 1 h). Following a washing step, bound Nb was detected with a mouse anti-HA antibody (catalog number H9658 Sigma Aldrich, MO, USA) and revealed with a goat anti-mouse IgG-peroxydase conjugate (catalog number A9044 Sigma Aldrich, MO, USA).

## Assessment of Nb Binding Affinity

The assessment of Nb binding affinity was performed using two methods: (i) indirect ELISA was carried out using a serial Nb dilution ranging from  $5 \times 10^{-7}$  to  $5 \times 10^{-12}$  M, as described above; (ii) Isothermal Fluorescence Titration

(IFT) was performed using recombinant murine TNC (mTNC, 700 nM, 0.01% Tween-20), as previously described with slight modifications (52). Briefly, the Nb concentration varied from 500 to 3,500 nM. The fluorescence emission spectra for mTNC/Nb complexes were collected and subsequently subtracted from emission spectra for mTNC and the resulting curves were then integrated. The mean values resulting from three independent measurements were plotted against the concentration of the added Nb. The resulting binding isotherms were analyzed by nonlinear regression using the program Origin (Microcal Inc., Northampton, MA, USA). The following equation describes the bimolecular association reaction, where  $F_i$  is the initial and  $F_{max}$  is the maximum fluorescence values. The  $KD$  is the dissociation constant, and  $[mTNC]$  and  $[Nb]$  are the total concentrations of the mTNC and the Nb ligand, respectively:

$$F = F_i + F_{max} \left[ \frac{KD + [mTNC] + [Nb]}{\sqrt{(KD + [mTNC] + [Nb])^2 - 4[mTNC][Nb]}} - 1 \right]$$

### Negative Electron Microscopy Imaging

The Nb/hTNC interaction complexes were visualized by negative staining and electron microscopy as previously described (53). Each Nb (20 nM) was conjugated with 5 nm colloidal gold particles (AuNPs) according to routinely used procedures (54). AuNP-Nb conjugates were incubated with hTNC (20 nM) for 30 minutes (min) at room temperature (RT) and subsequently negatively stained with 2% uranyl acetate. Specimens were assessed and electron micrographs were taken at 60 kV with a Phillips EM-410 electron microscope using imaging plates (Ditabis).

### Western Blot Analysis of TNC Specific Nb

Cell lysates (40  $\mu$ g) from HEK293, HEK293/hTNC, (20  $\mu$ g) NT193 and subclone NT193-1 cells (generated by limited dilution), RAW267 macrophages (ATCC) and DC2.4 dendritic cells (22) in RIPA buffer (catalog number R0278 SIGMA Aldrich, MO, USA) or purified human hTNC (hTNC, 100 ng) and murine TNC (mTNC, 50 ng) were boiled at 100°C for 5 min, before loading on a 4–20% gradient SDS/PAGE gel (catalog number 456-8095 Mini-PROTEAN TGX™, Bio-Rad Laboratories, Hercules, CA, USA), then, transferred onto a PVDF membrane (catalog number 1620174 Bio-Rad Laboratories, Hercules, CA, USA). After blocking with 5% milk, PBS/0.1% Tween-20 (catalog number 1706404 Bio-Rad Laboratories, Hercules, CA, USA) the membrane was incubated O/N at 4°C with Nb3 or Nb4 (2  $\mu$ g/mL). After three washing steps, the membrane was first incubated with a mouse anti-HA antibody (1 h 30 min at RT), and then with the anti-mouse IgG horseradish peroxidase conjugate diluted at 1:1,000 (catalog number AB\_772209, NXA931, Amersham GE Healthcare, USA). Immunocomplexes were revealed with ECL (catalog number 28 980926 Amersham GE healthcare, USA). A prestained protein ladder (10–250 kDa, catalog number 06P-0211 Euromedex, France) was used. Mouse monoclonal antibody B28.13 (1  $\mu$ g/mL), raised against hTNC was used as a positive control (55).

### Immunofluorescence Assay

Glioblastoma cell xenografts had previously been generated by subcutaneous injection of  $2 \times 10^6$  U87MG or U87MG-shTNC (TNC knockdown) cells into the flank of a nude mouse (56). Frozen (−80°C) sections were cut (7  $\mu$ m thickness), fixed with 4% paraformaldehyde (PFA) (catalog number 30525-89-4 Sigma Aldrich, MO, USA) for 15 min at RT, and permeabilized with 0.5% Triton X-100 in PBS and blocked with 10% normal donkey serum (NDS) in PBS for 2 h at RT (catalog number 017-000-121 Jackson ImmunoResearch Inc, USA). Sections were co-stained with the Nb and B28.13 antibody diluted in PBS, 10% NDS O/N at 4°C, rabbit anti-HA antibody (ab236632 abcam, UK, 1:1,000 dilution, 90 min at RT) and, donkey anti-mouse antibody labeled with Texas Red fluorophore (catalog number PA1-28626 Invitrogen, Carlsbad, CA, USA), and donkey anti-rabbit antibody labeled with Alexa Fluor 488 Green fluorophore (catalog number AB-2313584 Jackson Immuno Research Inc, USA) were used (1:1,000 dilution for 90 min at RT). After each antibody incubation, sections were washed five times with PBS. For staining of cell nuclei, sections were incubated with 4', 6-diamidino-2-phenylindole (DAPI, 0.2  $\mu$ g/mL, catalog number 32670 Sigma Aldrich, MO, USA) for 10 min at RT. Slides were sealed with a polymerization medium (Fluorsave™ Reagent, Calbiochem) underneath the coverslips and stored at 4°C until analysis. Pictures were taken with an AxioCam MRm (Zeiss) camera and Axiovision software.

### Human Tumor Samples and Analysis by Immunohistochemistry

Surgically removed tongue tumors, Formalin-Fixed Paraffin-Embedded (FFPE) embedded in FFPE, were retrieved from the tumor bank of the Centre Paul Strauss (Strasbourg, France). The FFPE-embedded 17/18G percutaneous needle biopsy of an hepatic metastasis derived from carcinoma of the gall bladder (CGB) was collected as part of a study involving human participants approved by the Mongi Slim University Hospital (MSUH) Committee on Medical Ethics (La Marsa, Tunisia) and the Ethikkommission Nordwest-und Zentralschweiz (Switzerland). Informed consent was obtained for all subjects. Characteristics of patients with oral squamous cell carcinoma (OSCC), or CGB liver metastasis, are summarized in **Supplementary Table 1**.

Immunohistochemical staining of OSCC samples was performed on serial 5  $\mu$ m deparaffinized tumor sections. For hTNC staining, intrinsic peroxidase was blocked by incubating sections with 3% hydrogen peroxide for 15 min and antigen retrieval was performed in Sodium Citrate (10 mM) buffer pH 6.0 at 95°C. Sections were blocked in 5% goat serum for 1 h, then incubated ON/4°C with rabbit anti-TNC antibody (#19011, Millipore, 1  $\mu$ g/mL) or anti-hTNC Nb (2  $\mu$ g/mL). After PBS rinsing, sections were incubated with biotinylated goat anti-rabbit or goat anti-lama antibodies (1 h at RT) then avidin-biotin (PK-4000, VECTASTAIN ABC Kit, Vector Lab, California, USA). Staining was revealed with 3, 3'-Diaminobenzidine developing solution (SK-4100, DAB, Vector Lab, California, USA) then sections were counterstained with hematoxylin.

After embedding in aqueous mounting medium, sections were examined using a Zeiss Axio Imager Z2 microscope. Pictures were taken with an AxioCam MRm (Zeiss, Axiovision) camera. The image acquisition setting (microscope, magnification, light intensity, exposure time) was kept constant per experiment and in between conditions. The origin of the tumor sample, patient gender, TNM stage, presence of metastasis and sampling date are depicted in **Supplementary Table 1**.

Immunohistochemical stainings of the CGB liver metastasis sample were performed on a Ventana Discovery Ultra instrument (Roche Diagnostics). The procedure RUO Discovery Universal was used with 40 min CC1 pre-treatment and anti-TNC B28.13 (1:5,000), Nb3 (1:100) or Nb4 (1:50) were applied manually and incubated for 1 h at 37°C. For Nb3 and Nb4, a rabbit anti-HA antibody (C29F4, Cell Signaling), used as a linker to detect the nanobodies, was applied manually (1:200) and incubated for 1 h at 37°C. Then, an anti-mouse antibody used for B28.13 (ImmPRESS reagent kit peroxidase anti-mouse Ig MP-7402, Vector Laboratories) or an anti-rabbit antibody used for Nb3 and Nb4 (ImmPRESS reagent kit peroxidase anti-rabbit Ig MP-7401, Vector Laboratories) were applied manually (200 µl) and incubated for 32 min at 37°C. Finally, the ChromoMap DAB kit (Roche Diagnostics) was used for detection and slides were counterstained with Hematoxylin II and Bluing Reagent (Roche Diagnostics) for 8 min.

### Boyden Chamber Transwell Chemoretention Assay

Boyden chamber transwell chemoretention assay of DC2.4 dendritic cells toward CCL21 was carried out as described previously (22). The bottom of the chamber was filled with DMEM containing human CCL21 (200 ng/mL, catalog number 366-6C-025 R&D Systems, Minneapolis, USA). The lower surface of the transwells was coated with purified horse fibronectin (FN) (37), rat collagen type I (Col I, catalog number 354236 BD Biosciences, FL, USA) or hTNC at a final concentration of 1 µg/cm<sup>2</sup> and incubated O/N with blocking solution alone or with the Nb, respectively. DC2.4 ( $5 \times 10^5$ ) cells resuspended in 150 µL of 1% FBS-complemented DMEM were placed into the top chamber of the transwell system. After 5 h of incubation at 37°C in 5% CO<sub>2</sub>, cells on the lower side of the insert were fixed with PFA and stained with DAPI before cell counting.

### Adhesion Assay

The adhesion assay was carried out on human KRIB osteosarcoma and human MES mesangial cells. Precisely, 96-well plates were coated with 1 µg/cm<sup>2</sup> FN, hTNC or with FN and hTNC together. Nbs were added at 500 nM after the coating for 1 h at 37°C. Plates were rinsed with PBS and the non-coated plastic surface was blocked with 1% BSA for 1 h. After blocking, KRIB osteosarcoma and MES were plated for 3 and 2 h, respectively, at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. After incubation, non adherent cells were removed by PBS washing and spread cells were stained with cristal violet and counted.

### Statistical Analysis

Statistical differences were analyzed by a two-way ANOVA test or a Kruskal-Wallis t-test, Student's test and Dunn's post-test. Statistical analyses were performed using the GraphPad Prism software. *p*-values < 0.05 or < 0.005 were considered as statistically significant. Data are expressed as the mean ± SEM.

### Structural Modeling of the Nb – TNC Interaction

For the Nb - TNC structural interaction modeling the Rosetta Antibody application (57, 58) from "ROSETTA 3.8"<sup>1</sup> was used. Selection of the top 10 Model was done according to Rosetta scoring based on system energy. Structural information about the 5th TNC fibronectin type III repeat (TN5) was extracted from the protein data bank deposited under the PDB code: 1TEN. The TN5 structure was refined using the ROSETTA relax application which then was used to map potential interaction sites in the selected Nb through the ZDOCK docking tool, version 3.0.2 (59). Structure and complex interactions were then visualized via the molecular visualization PyMOL software (60).

## RESULTS

### Generation of an Immune VHH Library to Produce hTNC- Specific Nanobodies

An immune response against hTNC had been elicited in the immunized dromedary as previously described (51). From PBMC, total RNA was extracted and cDNA was prepared. This cDNA was used as template to perform the first PCR using primers CALL001 and CALL002 specific for the variable domains of the heavy-chain isotypes (IgG1, IgG2, and IgG3), subsequently leading to the co-amplification of VH and VHH coding domains (**Supplementary Figure 1A**). As expected, because of the presence of CH1 domain in conventional antibodies (IgG1) and different hinge size in non-conventional antibodies (HCAs), three PCR products were observed by agarose gel electrophoresis: the 900, 790, and 720 bp fragments corresponding to the VH-CH1-Hinge-CH2 of the IgG1 and the VHH-Hinge-CH2 exons of the IgG2 and IgG3, respectively (**Supplementary Figure 1A**). Selective only-VHH fragments were successfully amplified using nested PCR specific-primers and cloned in pMECS phagemid (see above). The obtained hTNC-specific VHH library was estimated to contain approximately  $3 \times 10^6$  CFU/mL independent clones. The insert size of 19 randomly chosen clones was investigated by PCR. The library insertion rate with a VHH insert of the expected size was 78.94% (**Supplementary Figure 1D**).

A representative aliquot of the TG1 cells harboring the VHH antibody repertoire was rescued with the M13K07 helper phage to produce phage particles expressing the nanobodies. Following three rounds of phage display selection on solid-phase coated hTNC, enrichment for hTNC-specific phage particles was observed from the first round of panning onwards (**Supplementary Table 2**). Twenty-five periplasmic extracts

<sup>1</sup>The Rosetta software, <https://www.rosettacommons.org/software/license-and-download>

selected from randomly picked individual clones of biopanning rounds were checked by ELISA. Only clones scoring positively by ELISA without binding to unspecific proteins (AahI and BotI toxins, respectively) were retained (**Supplementary Figure 1E**). In total, eight recombinant clones displaying highest recognition and binding to the hTNC from the sequenced VHHs were selected. Two recombinant clones displayed identical amino-acid sequences (Nb3 and Nb5). The Nb3, Nb4, and Nb29 were selected for further investigation. As illustrated in **Figure 1A**, all hTNC-specific Nb sequences (Nb3, Nb4, and Nb29) exhibit the VHH hallmark amino acid residues in the framework-2 region (FR2 Phe42, Glu49, Arg50, and Gly52) and the conserved Trp at position 118 of the anchoring region. According to their common CDR1 sequence, Nb3 and Nb4 are most likely derived from the same V-D-J rearrangement and share the same B-cell progenitor (40). The difference in CDR3 length of the Nb29 corresponding sequence is remarkable (21 amino-acid residues). Interestingly, the Nb29 has a total of six cysteines (at positions 23, 33, 103, 108, 117, and 119) and therefore harbors two additional interloop disulfide bonds, in addition to the FR1/FR3 conventional ones (Cys23/Cys103). Nevertheless, because of its moderate binding to hTNC and low yield, Nb29 was not further investigated here.

The CDR3 residue length within the Nb3 and Nb4 sequences (17 amino-acid residues) was identical and no difference was noticed. The only divergence in the Nb3 and Nb4 sequences was observed at position 2 (Leu substituted by Val in FR1), at position 52 (Gly substituted by Ala in CDR2) and at position 92 (Asp substituted by Gly in FR3), respectively, suggesting an interaction with a common epitope on TNC.

## Production and Purification of hTNC Specific Nanobodies

Only clones that scored highly positive (**Supplementary Figure 1E**) were further used for flask production and Immobilized Metal Affinity Chromatography purification (IMAC), according to Hmila et al. (61). Briefly, production of each soluble anti-hTNC Nb was accomplished by transformation of *E. coli* WK6 cells with the corresponding recombinant phagemid. The amber stop codon located between the VHH insert and the gene III within the pMECS phagemid, resulted in expression of the Nb as soluble protein in the periplasm compartment of *E. coli*, leading to rapid IMAC purification of the Nb. As expected, the Coomassie-stained SDS/PAGE gel revealed the apparent molecular weight of 14 kDa (**Figure 1B**). The Nb3 and Nb4 production yields were estimated ranging from 0.6 to 0.8 mg/L, respectively, when flask cultured in TB medium. No bands indicative of contaminants or Nb degradation were detected.

Nb4 (5 µg/mL) displayed a higher ELISA binding titer toward hTNC (0.5 µg/mL,  $OD_{492nm} = 1.526$ ), compared to Nb3 (5 µg/mL,  $OD_{492nm} = 0.913$ ) and to the irrelevant nanobody (anti-BotI toxin nanobody, 5 µg/mL,  $OD_{492nm} = 0.118$ ) (**Figure 1C**, **Supplementary Figure 2**). Furthermore, immunoblotting assays revealed that both nanobodies showed a specific recognition of not only the purified hTNC (100 ng)

but also of TNC in the supernatant from HEK293/TNC cells. Parental HEK293 cells did not express TNC and also showed no signal with Nb3 nor Nb4 (**Figure 1D**).


As human and murine TNC are highly conserved (62) we used Nb3 and Nb4 for detection of murine TNC by western blot. Whereas, the monoclonal anti-TNC antibody MTn12 recognized recombinant mTNC expressed in HEK293/TNC cells indicated by the appearance of multiple bands, Nb3 and Nb4 did not recognize these TNC species (**Figure 1E**). There were several higher molecular weight bands of TNC recognized by MTn12 in recombinant TNC, NT193, and RAW267 cells. However, one or more of these bands at 250 kDa were well-recognized by Nb3 and Nb4 in NT193 cells but poorly in HEK293 and RAW267 cells. On the contrary TNC proteoforms (between 150 and 250 kDa) that were recognized by Nb3 and Nb4 in NT193-1, RAW267 and DC2.4 cells were not recognized by MTn12 (**Figure 1E**). There are several explanations for this result. First it is conceivable that the epitope recognized by MTn12 (which is not known) is different to that recognized by Nb3 and Nb4. Second Nb3 and Nb4 recognize a particular TNC conformation as epitope which is lost upon denaturation by SDS and boiling. Third, glycosylation may have an impact on the conformation of the epitope recognized by Nb3 and Nb4. Recently it was shown that N-glycosylation in TNC (in particular within TN5) impacted binding of the envelope protein of HIV (10). Apparently the conformation of the epitope recognized by Nb3 and Nb4 is still available in NT193 and the other murine cells despite denaturation as seen in **Figure 1E**. These bands are specific for TNC since unspecific anti-HA bands are below 85 kDa (63). In conclusion, Nb3 and Nb4 may recognize a conformational epitope in TNC that could be sensitive to denaturation and/or N-glycosylation which has to be further investigated in the future.

## Assessment of Nb3 and Nb4 Affinities for TNC by Isothermal Fluorescence Titration

By Isothermal Fluorescence Titration (IFT), we investigated the binding of Nb3 or Nb4 to fluorescently tagged mTNC until signal saturation and determined the dissociation constant ( $K_D$ ) as  $711 \times 10^{-9}$  M (Nb3) and  $537 \times 10^{-9}$  M (Nb4) that indicates a robust interaction (**Figure 1F**). In addition, ELISA assays were performed with Nb molar concentrations ranging from  $5 \times 10^{-7}$  to  $5 \times 10^{-12}$  M and revealed specific binding with a 50% Effective Concentration ( $EC_{50}$ ) of both Nb3 and Nb4 binding to hTNC at 10 and 5 nM, respectively, again revealing a strong interaction (**Figure 1G**).


## Detection of the Nanobody Binding Site in TNC by Negative Electron Microscopy

We investigated the location of the antigenic epitope in hTNC by negative electron microscopy where the nanobodies were coupled to gold beads. Upon incubation of hTNC with gold beads-bound nanobodies, we detected the gold particles along the length of the hTNC monomers and quantified them (**Figure 2A**). We observed a high number of Nb3 and Nb4 binding in the middle of the hTNC monomer resembling binding of several soluble factors in the fifth fibronectin type



**FIGURE 1 |** Specificity of the purified nanobodies for hTNC **(A)** Comparative alignment of amino acid sequences of nanobodies Nb3, Nb4, and Nb29 showing four amino acid hallmark changes at positions F42, E49, R50, and G52 according to the IMGT Scientific chart analysis for the V-Domain. Positioning of CDRs1-3 and Frameworks 1-4 are indicated. **(B)** SDS-PAGE analysis of the purified nanobodies Nb3 and Nb4. The nanobodies were expressed in bacteria and purified bacterial lysate was separated on a 15 % SDS-PAGE gel that was stained with Coomassie blue. Lanes represent MW: Prestained molecular weight marker, size indicated in kDa. 1, 2: Nb3 eluates 1 and 2. 3, 4: Nb4 eluates 1 and 2. 5: Purified periplasmic extract (PE) from Nb3 after induction. 6: Purified periplasmic extract from Nb4 after induction. Nb3 and Nb4 are visible at 15 kDa, the respective molecular weight of a nanobody. **(C)** Binding specificity assessment of Nb3 and Nb4 An amount of 50 ng hTNC was coated onto microtiter plates, and 500 ng (100  $\mu$ l) nanobodies were added. After incubation with a mouse anti-HA antibody and then anti-mouse HRP, absorbance at 492 nm was measured by an ELISA reader. NC, no coating. Values were the means of 3 independent experiments. Mean  $\pm$  SEM, \* $p$  < 0.05, \*\* $p$  < 0.01, Student's t-test. **(D)** Western blot analysis of Nb3 and Nb4 An amount of 40  $\mu$ g of total cell lysate from parental HEK293 (HEK) (devoid of TNC) and HEK:TNC (Continued)

**FIGURE 1** | (engineered to express hTNC) and 100 ng of purified hTNC were analyzed by Western blot for detection of TNC by B28.13 (monoclonal anti-hTNC antibody) or Nb3 and Nb4 (2  $\mu\text{g}/\text{mL}$ ). GAPDH was used as loading control. Representative result,  $n = 3$ . **(E)** Western blot of 50 ng of purified mTNC (22) and 20  $\mu\text{g}$  of total cell lysate of the indicated murine cells with GAPDH as loading control. Detection of TNC with the MTn12 antibody or Nb3 and Nb4, respectively. Representative result,  $n = 2$ . **(F)** Determination of the effective concentration (EC50) at which 50% of epitopes in hTNC are occupied by Nb3 (diamonds) and Nb4 (squares), respectively. The experiment was done in triplicates. Mean  $\pm$  SEM. \* $p < 0.05$ , Two-way ANOVA test. **(G)** Binding affinities of Nb3 and Nb4 for recombinant mTNC as measured by isothermal fluorescence titration. The experiment was done three times.



**FIGURE 2** | Identification of interaction sites of Nb3 and Nb4 in hTNC. **(A)** Binding of gold-labeled Nb3 and Nb4 to hTNC was determined by negative staining and transmission electron microscopy. The hTNC molecule in the absence or presence of Nb3 or Nb4 is depicted. Black dots represent binding sites for Nb3 and Nb4 in hTNC. **(B)** Quantification of Nb3 and Nb4 binding according to the position (nm) on TNC. Representation of a TNC monomer with oligomerization domain (triangle) to form hexamers as seen in **(A)**, FNIII repeats (gray boxes, constant domains, white boxes, alternative domains) and fibrinogen like domain (circle). Representative result of three independent experiments, displaying the quantification of 500 micrographs.


III repeat (FNIII) in TNC [TN5 (64)]. Nb3 and Nb4 showed a similar binding pattern suggesting that both nanobodies recognize the same or overlapping epitopes in hTNC, presumably TN5 (**Figure 2B**).

### Nanobodies Nb3 and Nb4 Recognize hTNC in Fresh Frozen and Paraffin-Embedded Human Tissues

Next, we investigated whether Nb3 and Nb4 recognized hTNC in FFFA tissues. Therefore, we stained human colon tissue from an ulcerative colitis (UC) patient and noticed a staining pattern that resembled published TNC expression in this tissue (65–67), (**Supplementary Figure 3A**). We also stained tissue from human tongue tumors (OSCC) with Nb3 and Nb4 and with a commercial rabbit polyclonal anti-TNC antibody on an adjacent section, and observed similar staining patterns for TNC reminiscent of tumor matrix tracks (TMT) that have previously been described [**Figure 3A**, (22)]. We also stained a liver metastasis from a patient with a

carcinoma of the gall bladder (CGB) (**Supplementary Table 1**) with Nb3 and Nb4 and observed a strong immunoreactivity of the stroma, similar to the staining observed with the anti-TNC antibody B28.13 (**Figure 3B**). This stromal staining resembled that of TNC expression in biliary tract cancers, including CGB liver metastasis as seen by conventional IHC (68).

Next we addressed recognition of murine and human TNC in tissues by IHC and IF. Therefore, we stained U87MG glioblastoma xenografted tumors where it was previously noticed that human TNC was largely more abundant than murine TNC by IHC and IF (56). We observed a fibrillar TNC signal in the U87MG tumors by IHC with Nb3 and Nb4 (**Figure 3C**) that overlapped with that of the B28.13 antibody signal, confirming specificity of the nanobodies for TNC (**Figure 3D**). As the U87MG tumors also express murine TNC but at much lower abundance (56), we stained U87MG tumors with a knockdown for human TNC in the grafted tumor cells and did not see a signal, suggesting that Nb3 and Nb4 at the chosen dilution recognize predominantly human TNC (**Figure 3E**).




## Nanobody Nb4 Counteracts the Anti-adhesive Properties of TNC on a FN/TNC Substratum

By using human osteosarcoma KRIB cells, we investigated whether Nb4 had an impact on cell rounding by TNC on a FN/TNC substratum. Previously, we had shown that cells are inhibited by TNC to spread on a combined FN/TNC substratum since TNC competed syndecan-4 binding to FN (44, 69). Here, we plated KRIB cells on FN, FN/TNC and TNC, respectively with or without Nb4. By staining with phalloidin (polymerized actin) and anti-vinculin (focal adhesions), we confirmed cell spreading on FN and cell rounding on FN/TNC and TNC, respectively. While cells had some actin stress fibers and focal adhesions on FN, addition of Nb4 did not change that (Figures 4A,B,


Supplementary Figure 4). However, upon addition of Nb4 to cells plated on FN/TNC we observed that cells spread in a Nb4 dose dependent manner with actin stress fibers and focal adhesions that looked similar to those in cells plated on FN (Figures 4A,B, Supplementary Figure 4). As in KRIB cells, both Nb3 and Nb4 restored adhesion of mesangial cells (MES) on a FN/TNC substratum suggesting that Nb3 and Nb4 blocked binding of TNC to FN (Figures 4C,D).

## Nanobodies Nb3 and Nb4 Abolished DC2.4 Chemoretention by TNC/CCL21

Previously, we had shown that in combination with CCL21 TNC immobilized dendritic DC2.4 cells (22). Here we used a Boyden chamber transwell migration assay to investigate whether Nb3



and Nb4 impacted chemoretenion by TNC. Therefore, we coated the lower surface of the insert with FN, collagen I (ColI) or TNC and added Nb3 or Nb4, respectively, and measured DC2.4 cell migration toward CCL21 placed in the lower chamber. We measured cells adhering on the coated surfaces in the presence or absence of the nanobodies and observed first a high number of cells being tethered on TNC but not the other coatings. Second, we noticed that the number of adherent cells dropped on TNC to that of the other coatings upon addition of Nb3 and Nb4 whereas no difference was seen with the other matrix coatings (**Figures 4E,F**).



### Three Dimensional Topology of the Nb3/TN5 Interaction Complex

We adopted a computational structure analysis strategy in order to identify amino acid residues involved in the interaction of Nb3 with TN5. The 1f2x (chain L), 3l95 (chain B), 5oc1 (chain G) and 5vak (chain B) structures were used as principal template for Nb3-frameworks, CDR1, CDR2 and CDR3, respectively. The number of generated Nb3 models was set to 1,000. The top ten model best scores, ranked according to an energy-based scoring were selected from 10 clusters composed of 100 structures per cluster then visually double checked (to detect structural anomalies) using the molecular visualization PyMOL software.

The TN5 structure (1TEN) was included in the Nb3 molecular docking simulation. The positively and negatively charged residues are in blue and red, respectively, whereas the neutral side-chains are indicated in white, showing clearly separated charges on the TN5 surface. Using the docking approach, we generated the top ten possible binding sites, ranked according to an energy-based scoring and filtered them to get a unique complex presenting the best molecular orientation with the most stable position (**Figure 5A**). In order to assess the main amino acid residues involved in the molecular Nb3-TN5 interaction, we used the COCOMAPS (bioCOMplexes COntact MAPS) web application server. A predicted intermolecular contact map of the Nb3-TN5 complex is illustrated in **Figure 5B** with a cut-off of 3 Å, highlighting the most crucial residues mainly implicated in the complex interaction. The predicted binding site residues in TN5 are as follows: N862, D850, N856-Q857, S859, I860, N837, Y858 interacting with Nb3 at position Y26, Y31, R44, S99, Y108, Y110, D111, Y112, W113. Interestingly, the CDR2 and CDR3 are predicted to dominate the interaction with TN5. Details of crucial residues involved in H bonds as proton donors or acceptors are described in **Supplementary Table 3**.

## DISCUSSION

The matrix, a highly abundant component of tumors, could be considered as a good tumor biomarker as matrix is often more stable than e.g., antigens expressed by tumor cells (70, 71). Furthermore, matrix seems to be accessible to antibodies and antibody derivatives in therapy (33). Detection of abundant tumor specific matrix could be useful for monitoring tumors and their progression. In this context, TNC is an intriguing matrix molecule, as it is highly expressed not only in tumors, but also in fibrosis and chronic inflammation often correlating with disease progression (4, 11, 72, 73). Hence, detection of high TNC levels in tissues and body fluids of patients with e.g., cancer or rheumatoid arthritis is a promising strategy (21, 22, 62). The large isoform of TNC, highly abundant in cancer tissue, may even be a good address for the delivery of drugs into the tumor (1). In particular, TNC-specific antibodies were shown to be a means for tumor targeting. In the past, several TNC-specific monoclonal antibodies were developed as well as aptamers and antibody fragments (scFv) that are currently undergoing clinical evaluation (37, 74–78). The anti-human TNC G11 antibody (79) was used for targeting TNC in glioma xenografts upon coupling with <sup>18</sup>F-fluorodeoxyglucose (37). Phase I and II clinical trials were performed with the F16 anti-TNC antibody in glioma patients (80, 81), breast cancer (82, 83) and Hodgkin's lymphoma (35). Coupling the TNC specific F16 antibody to IL-2 (Teleukin<sup>®</sup>) was used to deliver IL-2 into the cancer tissue (82, 84). Moreover, since 2013, a phase II clinical trial using Teleukin<sup>®</sup> labeled with <sup>131</sup>Iodine is in progress in melanoma patients (EudraCT 2012-004018-33) (35). These antibodies did not show any adverse effects and may be useful for tumor imaging. One needs to await the outcome of the clinical studies to see whether targeting TNC with these antibodies can also reduce tumor growth and potentially tumor progression (78).

Staining of FFPE tissues remains a challenge in the clinical practice due to frequent masking of epitopes. Also access of antibodies to their epitopes used in functionalized antibody assisted drug delivery remains a challenge. Due to their intrinsic characteristics, such as small size, high stability and good specificity, nanobodies constitute promising agents to overcome some of these limitations (85). Indeed, in a recently patented study covering another group of TNC specific nanobodies (86, 87), the authors demonstrated that the radioactive coupled nanobody <sup>64</sup>Cu-NJTs detected micrometastasis in tumor mice by life imaging. These results promise that TNC specific nanobodies could be used for delivery of therapeutic compounds into tumors or into other tissues with high TNC content.

In this report we aimed at the development of nanobodies directed against hTNC to detect TNC in FFPE tissues and to block TNC functions. We purified recombinant TNC of human origin and used this molecule to elicit a potent immune response in the dromedary. A substantial proportion of polyclonal heavy chain IgG subclasses bound to TNC and recognized TNC by IF staining in tumor tissue (51). This encouraged us to generate nanobodies. A VHH library from this dromedary was generated that met the required quality control standards (88, 89) and allowed us to isolate nanobodies that specifically recognized TNC. Although, the titer of dromedary antibodies against hTNC was significantly high, the *in vitro* selection of anti-hTNC binders from this specific VHH library allowed us to retrieve only eight binders after three rounds of bio-panning. A possible explanation of this limited sequence diversity of binders might be attributed to our screening condition as we immobilized hTNC which potentially has masked the epitopes or prevented nanobodies to bind due to sterical hindrance. To retrieve nanobodies recognizing additional TNC sequences, future biopanning could be done by using soluble TNC.

In this paper, we have generated eight human TNC specific nanobodies and the two best in class candidates (Nb3, Nb4) in terms of binding strength and specificity were further characterized in more detail. The amino acid sequences of the three TNC-specific Nb revealed a high degree of identity with human VH sequences of family III; however the VHH imprints were clearly present (90, 91).

Nb3 and Nb4 recognized specifically TNC by immunoblotting, ELISA and negative EM imaging and by staining of PFA and FFPE fixed human tissues. We identified binding of Nb3 and Nb4 in the center of the TNC monomer around TN5 which may be a particularly exposed site in TNC as TN5 was shown to bind several soluble factors (22, 64). Future studies have to address whether TN5 is particular in raising an immune response. It is interesting to note N-glycosylation sites in TN5 and that N-glycosylation is important for the envelope proteins of HIV to bind TNC (10). In this context it will be interesting to learn more about the antigenic epitope properties of the NJTs nanobodies and to see whether the epitopes are different.

Both nanobodies exhibited a TNC specific staining in all tested tissues confirming the aptitude of Nb3 and Nb4 to recognize native TNC *in situ*. As our study is limited to a few examples as proof of concept, more stainings of FFPE embedded tissues have

to be done in the future. It is important to compare Nb3 and Nb4 stainings with established anti-TNC antibody staining protocols to determine whether staining patterns are similar or different. *In silico*, 3D modeling of the interaction of Nb3 with TN5 revealed the potential contribution of CDR2 and CDR3 in the interaction with critical hydrophobic amino acid residues in TN5. Future site directed mutagenesis experiments have to evaluate the predicted nanobody-TN5 interaction sites in particular taking into account a potential role of N-glycosylation.

The Nb3 and Nb4 nanobodies may be suitable for a sandwich ELISA assay. There is a need for a robust ELISA assay to detect TNC in body fluids such as blood and urine to be used as parameters for earlier diagnosis of diseases with high TNC levels (11, 12, 92, 93). Only few commercial ELISA kits are available. A frequently used one recognizes the FNIII domain that is not present in all TNC proteoforms and thus may miss TNC species lacking this domain (94). Thus, an advantage of using Nb3 and Nb4 for ELISA is that they recognize an epitope in the constant FNIII domains (likely in TN5) thereby potentially detecting more TNC isoforms.

To respond to the need of high Nb3 and Nb4 yields for applications mentioned above the expression conditions have to be optimized in the future as the production yields of Nb3 and Nb4 varied and were not very high.

Finally, we observed that Nb3 and Nb4 recognized not only human TNC but also murine TNC as seen by immunoblotting and IFT with a  $K_D$  value in the three digits nanomolar range comparable to other molecules binding TNC [TGF- $\beta$ 1,  $K_D$  = 20.3 nM (64); CCL21,  $K_D$  = 58 nM (22); FN III13,  $K_D$  = 128 nM (44)]. Therefore, these nanobodies may be useful for preclinical models assessing tumor growth by life imaging, delivery of drugs into tissues with high TNC levels or even to inhibit TNC actions in tumors as we observed that both Nb3 and Nb4 inhibited TNC-induced cell rounding, and TNC specific retention of immune cells in the matrix. Thus, our nanobodies could be suitable to inhibit TNC functions in cancer cell migration and invasion and to ablate immune-suppressive functions of TNC in cancer. As a major binding site for the envelope protein in HIV was found in TN5 (10), Nb3 and Nb4 may be useful to modulate this interaction. Finally, Nb3 and Nb4 may also be useful to target TNC actions in COVID19 as high TNC levels correlated with severity of the disease symptoms (13). Our results provide a rationale for a future clinical evaluation of the hTNC-specific Nbs.

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## ETHICS STATEMENT

The Institutional Review Board of the Centre de Ressources Biologiques (Association française de normalisation:

2010/39043.2) of the Hautepierre hospital (Strasbourg, France) and Centre Paul Strauss have approved the study on human Ulcerative Colitis samples and human OSCC, respectively. The patients/participants provided their written informed consent to participate in the study.

## AUTHOR CONTRIBUTIONS

SD contributed by library construction, nanobody selection, characterization of the nanobodies, and writing the manuscript. RB contributed to the library construction and nanobody selection. WE, TL, CA-F, and AKs contributed by characterization of the TNC blocking functions of the nanobodies. DM, AKs, SB, and IH contributed to the characterization of the nanobodies. MM contributed to characterization of the nanobody TNC interaction by negative electron microscopy. ZB contributed to the dromedary veterinary management and immunizations. RC-E contributed by funding, supervision, and validation. GO contributed by funding, supervision, validation, manuscript writing, and review and editing. BB-Z led the project, contributed by funding, supervision, validation, manuscript writing, and review and editing. All authors contributed to the article and approved the submitted version.

## FUNDING

This work was funded by grants from Institut Pasteur Tunis, PRF D4P1 project, Tunisia, to BB-Z, Friedrich Miescher Institute, Basel, Switzerland to RC-E and ANR-AngioFib, ANR-ACKITEC, INCa/Ligue contre le Cancer ECMpact, University Strasbourg and INSERM to GO and personal fellowships to WE (French Ministry of Research MRT) and DM (Association pour la recherche sur le cancer ARC).

## ACKNOWLEDGMENTS

We like to thank Dr. H. Bannour, M. Vet for his invaluable help on dromedary immunization. We thank Prof. Lotfi Hendaoui and Prof. Ahlem Lahmar for providing the CGB hepatic metastasis FFPE tissue and the associated clinicopathological diagnosis. We like to acknowledge Agnes Neuville (Department of Pathology, HUS Hautepierre) for providing the UC specimens and Tristan Rupp for having generated the U87MG tumors. We are sincerely sad that we cannot share the accomplished work with RC-E who had initiated this project together with BB-Z.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2021.635166/full#supplementary-material>

## REFERENCES

- Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, et al. Clinical significance of large Tenascin-C spliced variant as a potential biomarker for colorectal cancer. *World J Surg.* (2007) 31:388–94. doi: 10.1007/s00268-006-0328-6
- Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. *Breast Cancer Res.* (2009) 11. doi: 10.1186/bcr2251
- Alharth AS, Alyami WA. Tenascin-C (TNC) promotes breast cancer cell invasion and proliferation: functional effects of TNC knockdown in highly invasive breast cancer cell lines. *Am J Med Biol Res.* (2016) 3:55–61. doi: 10.12691/ajmbr-3-2-2
- Shen C, Wang C, Yin Y, Chen H, Yin X, Cai Z, et al. Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs. *Medicine.* (2019) 98:e14045. doi: 10.1097/MD.00000000000014045
- Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. *Clin Cancer Res.* (1995) 9:1035–41.
- Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. *Cancer.* (2003) 98:2430–9. doi: 10.1002/cncr.11796
- Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of tenascins. *BioEssays.* (1995) 17:873–8. doi: 10.1002/bies.950171009
- Erickson HP, Bourdon MA. Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. *Annu Rev Cell Biol.* (1989) 5:72–92. doi: 10.1146/annurev.cb.05.110189.000443
- Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS. Tenascins in stem cell niches. *Matrix Biol.* (2014) 37:112–23. doi: 10.1016/j.matbio.2014.01.007
- Mangan RJ, Stamper L, Ohashi T, Eudailey JA, Go EP, Jaeger FH, et al. Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. *Mucosal Immunol.* (2019) 12:1004–12. doi: 10.1038/s41385-019-0164-2
- Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress: Tenascins in pathological stress. *J Pathol.* (2003) 200:488–99. doi: 10.1002/path.1415
- Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. *J Cell Commun Signal.* (2009) 3:287–310. doi: 10.1007/s12079-009-0075-1
- Zeng H, Chen D, Yan J, Yang Q, Han Q, Li S, et al. Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients. *FEBS J.* (2020) 287:febs.15609. doi: 10.1111/febs.15609
- Saupe F, Schwenzer A, Jia Y, Gasser I, Spenlé C, Langlois B, et al. Tenascin-C downregulates Wnt inhibitor Dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. *Cell Rep.* (2013) 5:482–92. doi: 10.1016/j.celrep.2013.09.014
- Sun Z, Velázquez-Quesada I, Murdamoohoo D, Ahowesso C, Yilmaz A, Spenlé C, et al. Tenascin-C increases lung metastasis by impacting blood vessel invasions. *Matrix Biol.* (2019) 83:26–47. doi: 10.1016/j.matbio.2019.07.001
- Oskarsson T, Acharyya S, Zhang XH-F, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. *Nat Med.* (2011) 17:867–74. doi: 10.1038/nm.2379
- Lowy CM, Oskarsson T. Tenascin C in metastasis: a view from the invasive front. *Cell Adhes Migr.* (2015) 9:112–24. doi: 10.1080/19336918.2015.1008331
- Langlois B, Saupe F, Rupp T, Arnold C, Van der Heyden M, Orend G, et al. AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. *Oncotarget.* (2014) 18:10529–45. doi: 10.18632/oncotarget.2470
- Bellone M, Caputo S, Jachetti E. Immunosuppression via Tenascin-C. *Oncoscience.* (2015) 2:667. doi: 10.18632/oncoscience.210
- Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, et al. Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation. *Cancer Res.* (2015) 75:2095–108. doi: 10.1158/0008-5472.CAN-14-2346
- Deligne C, Murdamoohoo D, Gammage AN, Gschwandtner M, Erne W, Loustau T, et al. Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype. *Cancer Immunol Res.* (2020) 8:368–82. doi: 10.1158/2326-6066.CIR-19-0276
- Spenlé C, Loustau T, Murdamoohoo D, Erne W, Beghelli-de la Forest Divonne S, Veber R, et al. Tenascin-C orchestrates an immune-suppressive tumor microenvironment in oral squamous cell carcinoma. *Cancer Immunol Res.* (2020) 8:1122–38. doi: 10.1158/2326-6066.CIR-20-0074
- Giblin SP, Midwood KS. Tenascin-C: form versus function. *Cell Adhes Migr.* (2015) 9:48–82. doi: 10.4161/19336918.2014.987587
- Dandachi N, Hauser-Kronberger C, MoreÀ E, Wiesener B, Hacker GW, Dietze O, et al. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. *J Pathol.* (2000) 193:181–9. doi: 10.1002/1096-9896(2000)9999:99993.0.CO;2-V
- Maschler S, Grunert S, Danielopol A, Beug H, Wirl G. Enhanced tenascin-C expression and matrix deposition during Ras/TGF- $\beta$ -induced progression of mammary tumor cells. *Oncogene.* (2004) 23:3622–33. doi: 10.1038/sj.onc.1207403
- Tucker RP, Chiquet-Ehrismann R. Tenascin-C: its functions as an integrin ligand. *Int J Biochem Cell Biol.* (2015) 65:165–8. doi: 10.1016/j.biocel.2015.06.003
- Li Z-L, Zhang H-L, Huang Y, Huang J-H, Sun P, Zhou N-N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. *Nat Commun.* (2020) 11:3806. doi: 10.1038/s41467-020-17395-y
- Hicke BJ, Marion C, Chang Y-F, Gould T, Lynott CK, Parma D, et al. Tenascin-C aptamers are generated using tumor cells and purified protein. *J Biol Chem.* (2001) 276:48644–54. doi: 10.1074/jbc.M104651200
- Zukiel R, Nowak S. Suppression of human brain tumor with interference RNA specific for tenascin-C. *Cancer Biol Therapy.* (2006) 5:1002–7. doi: 10.4161/cbt.5.8.2886
- Rolle K, Nowak S, Wyszko E, Nowak M, Zukiel R, Piestrzeniewicz R, et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). *Cancer Biol Therapy.* (2010) 9:397–407. doi: 10.4161/cbt.9.5.10958
- Rolle K. miRNA Multiplayers in glioma. From bench to bedside. *Acta Biochim Polonica.* (2015) 62:353–65. doi: 10.18388/abp.2015\_1072
- Grabowska M, Grześkowiak BF, Szutkowski K, Wawrzyniak D, Głodowicz P, Barciszewski J, et al. Nano-mediated delivery of double-stranded RNA for gene therapy of glioblastoma multiforme. *PLoS ONE.* (2019) 14:e0213852. doi: 10.1371/journal.pone.0213852
- Brack SS. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. *Clin Cancer Res.* (2006) 12:3200–8. doi: 10.1158/1078-0432.CCR-05-2804
- Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. *J Nucl Med.* (2013) 54:397–401. doi: 10.2967/jnumed.112.111310
- Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, et al. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging.* (2014) 41:867–77. doi: 10.1007/s00259-013-2658-6
- Petronzelli F. Improved tumor targeting by combined use of two antitenascin antibodies. *Clin Cancer Res.* (2005) 11:7137s–45s. doi: 10.1158/1078-0432.CCR-1004-0007
- Silacci M. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors *in vivo*. *Protein Eng Design Select.* (2006) 19:471–8. doi: 10.1093/protein/gz1033
- Saerens D, Muyldermans S, (eds). *Single Domain Antibodies: Methods and Protocols*. Totowa, NJ: Humana Press (2012).
- Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. *FASEB J.* (2010) 24:3479–89. doi: 10.1096/fj.09-148213
- Conrath KE, Lauwereys M, Galleni M, Matagne A, Re J-ME, Kinne JR, et al.  $\beta$ -Lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. *Antimicrob Agents Chemother.* (2001) 45:6. doi: 10.1128/AAC.45.10.2807-2812.2001

41. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. *J Mol Biol.* (2008) 382:779–89. doi: 10.1016/j.jmb.2008.07.054
42. Ebrahimizadeh W, Mousavi Gargari S, Rajabibazl M, Safae Ardekani L, Zare H, Bakherad H. Isolation and characterization of protective anti-LPS nanobody against *V. cholerae* O1 recognizing Inaba and Ogawa serotypes. *Appl Microbiol Biotechnol.* (2013) 97:4457–66. doi: 10.1007/s00253-012-4518-x
43. De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. *Trends Biotechnol.* (2014) 32:263–70. doi: 10.1016/j.tibtech.2014.03.001
44. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of Tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. *Cancer Res.* (2001) 61:8586–94. Available online at: <https://cancerres.aacrjournals.org/content/canres/61/23/8586.full.pdf>
45. Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G, et al. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. *Cancer Res.* (2007) 67:9169–79. doi: 10.1158/0008-5472.CAN-07-0666
46. Ehrismann R, Chiquet M, Turner DC. Mode of action of fibronectin in promoting chicken myoblast attachment. *J Biol Chem.* (1981) 256:4056–62. doi: 10.1016/S0021-9258(19)69564-5
47. Fischer D, Brown-Lüdi M, Schulthess T, Chiquet-Ehrismann R. Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. *J Cell Sci.* (1997) 110:1513–22.
48. Fischer D, Chiquet-Ehrismann R, Bernasconi C, Chiquet M. A single heparin binding region within fibrinogen-like domain is functional in chick tenascin-C. *J Biol Chem.* (1995) 270:3378–84. doi: 10.1074/jbc.270.7.3378
49. Vincke C, Gutiérrez C, Wernery U, Devoogdt N, Hassanzadeh-Ghassabeh G, Muyldermans S. Generation of single domain antibody fragments derived from camelids generation of manifold constructs. In: Nevoltris D., Chames P. editors. *Antibody Engineering*. Totowa, NJ: Humana Press (2012). p. 145–76.
50. Abderrazek RB, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, et al. Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. *Biochem J.* (2009) 424:263–72. doi: 10.1042/BJ20090697
51. Dhaouadi S, Murdamoothoo D, Tounsi A, Erne W, Benabderrazek R, Benlasfar Z, et al. Generation and characterization of dromedary Tenascin-C and Tenascin-W specific antibodies. *Biochem Biophys Res Commun.* (2020) 530:471–8. doi: 10.1016/j.bbrc.2020.05.077
52. Gerlza T, Hecher B, Jeremic D, Fuchs T, Gschwandtner M, Falsone A, et al. A combinatorial approach to biophysically characterise chemokine-glycan binding affinities for drug development. *Molecules.* (2014) 19:10618–34. doi: 10.3390/molecules190710618
53. Westman J, Hansen FC, Olin AI, Mörgelin M, Schmidtchen A, Herwald H. p33 (gC1q receptor) prevents cell damage by blocking the cytolytic activity of antimicrobial peptides. *J Immunol.* (2013) 191:5714–21. doi: 10.4049/jimmunol.1300596
54. Baschong W, Wrigley NG. Small colloidal gold conjugated to fab fragments or to immunoglobulin g as high-resolution labels for electron microscopy: a technical overview. *J Electron Microscop Tech.* (1990) 14:313–23. doi: 10.1002/jemt.1060140405
55. Schenk S, Muser J, Vollmer G, Chiquet-Ehrismann R. Tenascin-C in serum: a questionable tumor marker. *Int J Cancer.* (1995) 61:443–9. doi: 10.1002/ijc.2910610402
56. Rupp T, Langlois B, Koczorowska MM, Radwanska A, Sun Z, Hussenet T, et al. Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling. *Cell Rep.* (2016) 17:2607–19. doi: 10.1016/j.celrep.2016.11.012
57. Weitzner B, Jeliakzov J, Lyskov S, Marze N, Kuroda D, Frick R, et al. Modeling and docking of antibody structures with Rosetta. *Nat Protoc.* (2017) 12:401–16. doi: 10.1038/nprot.2016.180
58. Ksouri A, Ghedira K, Ben Abderrazek R, Shankar Gowri BA, Benkahla A, Bishop Tastan O, et al. Homology modeling and docking of AahII-Nanobody complexes reveal the epitope binding site on AahII scorpion toxin. *Biochem Biophys Res Commun.* (2018) 496:1025–32. doi: 10.1016/j.bbrc.2018.01.036
59. Pierce BG, Wiehe K, Hwang H, Kim BH, Vreven T, Weng Z. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. *Bioinformatics.* (2014) 30:1771–3. doi: 10.1093/bioinformatics/btu097
60. Schrödinger LLC. *The PyMOL Molecular Graphics System, Version 1.3r1*. Portland, OR: Schrödinger, LLC (2010).
61. Hmila I, Ben Abdallah R, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. *Mol Immunol.* (2008) 45:3847–56. doi: 10.1016/j.molimm.2008.04.011
62. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. *Experientia.* (1995) 51:853–62. doi: 10.1007/BF01921736
63. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. *mBio.* (2010) 1:e00018–10. doi: 10.1128/mBio.00018-10
64. De Laporte L, Rice JJ, Tortelli F, Hubbell JA. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. *PLoS ONE.* (2013) 18:e62072. doi: 10.1371/journal.pone.0062076
65. Spenlé C, Lefebvre O, Lacroute J, Méchine-Neuville A, Barreau F, Blottière HM, et al. The laminin response in inflammatory bowel disease: protection or malignancy? *PLoS ONE.* (2014) 9:e111336. doi: 10.1371/journal.pone.0111336
66. Kawamura T, Yamamoto M, Suzuki K, Suzuki Y, Kamishima M, Sakata M, et al. Tenascin-C produced by intestinal myofibroblasts promotes colitis-associated cancer development through angiogenesis. *Inflamm Bowel Dis.* (2019) 25:732–41. doi: 10.1093/ibd/izy368
67. Ning L, Li S, Gao J, Ding L, Wang C, Chen W, et al. Tenascin-C is increased in inflammatory bowel disease and is associated with response to infliximab therapy. *BioMed Res Int.* (2019) 2019:1–9. doi: 10.1155/2019/1475705
68. Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, et al. Tenascin-W is a novel stromal marker in biliary tract cancers. *Front Immunol.* (2021) 11:1–12. doi: 10.3389/fimmu.2020.630139
69. Sun Z, Schwenzer A, Rupp T, Murdamoothoo D, Vegliante R, Lefebvre O, et al. Tenascin-C promotes tumor cell migration and metastasis through integrin  $\alpha 9 \beta 1$ -mediated YAP inhibition. *Cancer Res.* (2018) 78:950–61. doi: 10.1158/0008-5472.CAN-17-1597
70. Venning FA, Wullkopf L, Erler JT. Targeting ECM disrupts cancer progression. *Front Oncol.* (2015) 5:224. doi: 10.3389/fonc.2015.00224
71. Genova C, Rijavec E, Grossi F. Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage? *J Thorac Dis.* (2017) 9:4300–4. doi: 10.21037/jtd.2017.10.66
72. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. *Cancer Lett.* (2006) 244:143–63. doi: 10.1016/j.canlet.2006.02.017
73. Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. *J Cell Sci.* (2016) 129:4321–7. doi: 10.1242/jcs.190546
74. Akabani B, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, et al. Dosimetry and radiographic analysis of 131I-labeled Anti-Tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II Study.11. *Int J Radiat Oncol Biol Phys.* (2000) 46:947–56. Available online at: <https://jnm.snmjournals.org/content/40/4/631.long>
75. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. *Exp Rev Anticancer Ther.* (2007) 7:675–87. doi: 10.1586/14737140.7.5.675
76. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. *Leuk Res.* (2009) 33:1718–22. doi: 10.1016/j.leukres.2009.06.025
77. Ko HY, Choi K-J, Lee CH, Kim S. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin  $\alpha \beta 3$  and tenascin-C proteins. *Biomaterials.* (2011) 32:1130–8. doi: 10.1016/j.biomaterials.2010.10.034
78. Spenlé C, Gasser I, Saupé F, Janssen K-P, Arnold C, Klein A, et al. Spatial organization of the tenascin-C microenvironment in experimental and human cancer. *Cell Adhes Migr.* (2015) 9:4–13. doi: 10.1080/19336918.2015.1005452
79. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, et al. Identification of a glioblastoma-associated tenascin-C isoform by

- a high affinity recombinant antibody. *Am J Pathol.* (1999) 154:1345–52. doi: 10.1016/S0002-9440(10)65388-6
80. Paganelli G, Magnani P, Zito F, Lucignani G, Sudati F, Truci G, et al. Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. *Eur J Nucl Med.* (1994) 21:314–21. doi: 10.1007/BF00947966
  81. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma—phase I and II study. *Acta Oncol Stockh Swed.* (1999) 38:351–9. doi: 10.1080/028418699431438
  82. Catania C, Maur M, Berardi R, Rocca A, Giacomo AMD, Spitaleri G, et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. *Cell Adhes Migr.* (2015) 9:14–21. doi: 10.4161/19336918.2014.983785
  83. De Braud FG, Catania C, Onofri A, Pierantoni C, Cascinu S, Maur M, et al. Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trials. *J Clin Oncol.* (2011) 29:2595. doi: 10.1200/jco.2011.29.15\_suppl.2595
  84. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. *N Engl J Med.* (1996) 335:1350–6. doi: 10.1056/NEJM199610313351803
  85. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, et al. Isolation and characterization of anti-Fc RIII (CD16) llama single-domain antibodies that activate natural killer cells. *Protein Eng Des Sel.* (2007) 21:1–10. doi: 10.1093/protein/gzm064
  86. Jaiikhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. *Proc Natl Acad Sci USA.* (2019) 116:14181–90. doi: 10.1073/pnas.1817442116
  87. Hynes RO. *Nanobody Based Imaging Targeting of ECM in Disease Development.* U.S. Patent No 20190225693. Massachusetts, MA: U.S. Patent and Trademark office (2019).
  88. Li T, Huang M, Xiao H, Zhang G, Ding J, Wu P, et al. Selection and characterization of specific nanobody against bovine virus diarrhea virus (BVDV) E2 protein. *PLoS ONE.* (2017) 12:e0178469. doi: 10.1371/journal.pone.0178469
  89. Wan R, Liu A, Hou X, Lai Z, Li J, Yang N, et al. Screening and antitumor effect of an anti-CTLA-4 nanobody. *Oncol Rep.* (2017) 39:511–8. doi: 10.3892/or.2017.6131
  90. Lefranc M-P, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. *Dev Comp Immunol.* (2003) 27:55–77. doi: 10.1016/S0145-305X(02)00039-3
  91. Noël F, Malpertuy A, de Brevern AG. Global analysis of VHHs framework regions with a structural alphabet. *Biochimie.* (2016) 131:11–9. doi: 10.1016/j.biochi.2016.09.005
  92. Raza K, Schwenzer A, Juarez M, Venables P, Filer A, Buckley DC, et al. Detection of antibodies to citrullinated tenascin-C in patients with early synovitis is associated with the development of rheumatoid arthritis. *RMD Open.* (2016) 2:2: e000318. doi: 10.1136/rmdopen-2016-000318
  93. Ishizaki J, Takemori A, Suemori K, Matsumoto T, Akita Y, Sada K et al. Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Res Ther.* (2017) 19:218. doi: 10.1186/s13075-017-1429-3
  94. Giblin S, Schwenzer A, Midwood KS. Alternative splicing controls cell lineage-specific responses to endogenous innate immune triggers within the extracellular matrix. *Matrix Biol.* (2020) 93:95–114. doi: 10.1016/j.matbio.2020.06.003

**Conflict of Interest:** MM was employed by Colzyx AB.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Dhaouadi, Ben Abderrazek, Loustau, Abou-Faycal, Ksouri, Erne, Murdamoothoo, Mörgelin, Kungl, Jung, Ledrappier, Benlasfar, Bichet, Chiquet-Ehrismann, Hendaoui, Orend and Bouhaouala-Zahar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.